Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Dysbindin CRISPR Activation Plasmid (m): sc-430148-ACT
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Dysbindin CRISPR Activation Plasmid (m) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- Dysbindin CRISPR Activation Plasmid (m) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by Dysbindin CRISPR Activation Plasmid (m) and Dysbindin CRISPR Activation Plasmid (m2) target distinct regulatory regions upstream of the Dtnbp1 transcriptional start site. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Dysbindin Antibody (D-8): sc-390626
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Dysbindin CRISPR Activation Plasmid (m) | sc-430148-ACT | 20 µg | $397.00 |
Mouse Dtnbp1 encodes dysbindin, a cytosolic and endosomal protein that functions as a core component of the BLOC-1 complex, coordinating endosome-to-lysosome trafficking, cargo sorting, and regulated secretion. Dysbindin contributes to synaptic vesicle biogenesis and neurotransmitter release by influencing vesicular pathways and actin-associated membrane dynamics, linking intracellular transport to neuronal circuit function. In addition to roles in neural tissue, Dtnbp1-dependent trafficking impacts lysosome-related organelles and receptor turnover, shaping cell signaling outputs. Altered DTNBP1 expression or function has been associated with neuropsychiatric disease biology and synaptic dysfunction, supporting its use in mechanistic studies of brain-relevant pathways.
Dysbindin CRISPR Activation Plasmid (m) provides a targeted, non-destructive approach to upregulating endogenous Dtnbp1 expression without altering the underlying DNA sequence.
Dysbindin CRISPR Activation Plasmid (m) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the Dtnbp1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the Dtnbp1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous Dysbindin expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native Dtnbp1 locus and enabling the study of Dysbindin-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of Dysbindin pathway restoration in tumor cells with silenced or reduced Dtnbp1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.